ClearPoint Neuro, Inc. (CLPT)
| Market Cap | 336.14M +9.1% |
| Revenue (ttm) | 36.97M +17.8% |
| Net Income | -25.54M |
| EPS | -0.90 |
| Shares Out | 29.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 427,590 |
| Open | 11.60 |
| Previous Close | 11.78 |
| Day's Range | 11.05 - 11.79 |
| 52-Week Range | 8.27 - 30.10 |
| Beta | 1.18 |
| Analysts | Strong Buy |
| Price Target | 20.00 (+78.41%) |
| Earnings Date | May 8, 2026 |
About CLPT
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint softwa... [Read more]
Financial Performance
In 2025, ClearPoint Neuro's revenue was $36.97 million, an increase of 17.78% compared to the previous year's $31.39 million. Losses were -$25.54 million, 35.0% more than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for CLPT stock is "Strong Buy" and the 12-month stock price target is $20.0.
News
ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
SOLANA BEACH, CA / ACCESS Newswire / April 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brai...
ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint
Combined clearance of the navigation and drug delivery technologies enables Canadian neurosurgery centers to leverage the Company's flagship image-guidance workflow and advances ClearPoint Neuro's ove...
ClearPoint Neuro Earnings Call Transcript: Q4 2025
2025 saw record revenue growth, a successful IRRAS acquisition, and strong momentum into 2026, with all core segments expected to grow double digits. Guidance for 2026 is $52M–$56M, reflecting FDA and integration factors, and long-term targets remain ambitious.
ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results
Record Revenue and IRRAS Holdings Acquisition Highlight the Company's 'Fast. Forward.' Strategy SOLANA BEACH, CA / ACCESS Newswire / March 17, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company...
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2025 Results March 17, 2026
SOLANA BEACH, CA / ACCESS Newswire / March 6, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the b...
ClearPoint Neuro Gets EU Green Light For Updated Brain Surgery Software
ClearPoint Neuro, Inc. (NASDAQ: CLPT) on Friday said it received EU MDR Certification for its ClearPoint Navigation Software Version 3.0.2.
ClearPoint Neuro Announces EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, Expanding Access to the Latest Operating Room Navigation Platform in Europe
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigati...
ClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue
The Company Achieved 20% Comparable Sales Growth in the Fourth Quarter of 2025 at $10.4 Million SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 12, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (th...
ClearPoint Neuro Completes Acquisition of IRRAS
Acquisition Will Enhance ClearPoint Neuro's Commercial Scale, Drive Operational Leverage, and Support Its Long-Term Strategy in CNS Drug Delivery Innovation SOLANA BEACH, CALIFORNIA / ACCESS Newswire ...
ClearPoint Neuro Reports Third Quarter 2025 Results
Site Readiness Continues for Specialized Treatment Centers Envisioned to Support a Growing Number of Cell and Gene Therapy Trial Patients and Later Commercialization SOLANA BEACH, CA / ACCESS Newswire...
ClearPoint Neuro Announces Agreement to Acquire IRRAS
Acquisition Will Further Expand the Potential of ClearPoint Neuro's Drug Delivery Portfolio While Immediately Adding New Indications and Commercial Scale Across a $0.5 Billion Market for the Treatment...
ClearPoint Neuro Earnings Call Transcript: Q3 2025
Q3 revenue grew 9% year-over-year to $8.9 million with gross margin rising to 63%. The IRRAS acquisition expands access to a $500 million neurocritical care market, and 2026 combined revenue is forecast at $54–$60 million. Integration and new CRO capacity are expected to drive future growth.
ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2025
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / November 5, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigati...
ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 7, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigatio...
ClearPoint Neuro Announces Expanded International Clearances for Key Therapy Delivery Product; Now Totaling 34 Countries Worldwide
The clearly established history across global regulatory bodies is expected to de-risk BioPharma partners' pathways towards achieving global scale and standardization. SOLANA BEACH, CALIFORNIA / ACCES...
ClearPoint Neuro Announces Development and Demonstration of the Company's Proprietary Robotic Neuro-Navigation System
New Product Category Will Enable Added Flexibility to Support Commercial Launches of Cell and Gene Therapy SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 1, 2025 / ClearPoint Neuro, Inc. (Nasdaq...
ClearPoint Neuro Announces the Appointment of Dr. Paul Larson as Chief Medical Officer
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / September 25, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise naviga...
ClearPoint Neuro Announces FDA Clearance Expanding Compatibility of the ClearPoint Prism Neuro Laser Therapy System with 1.5T MRI Scanners
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / September 4, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigat...
ClearPoint Neuro Earnings Call Transcript: Q2 2025
Q2 2025 revenue grew 17% year-over-year to $9.2M, driven by strong performance across all segments and record adoption of new products. Cash position strengthened to $41.5M, supporting global expansion and ongoing investments in cell and gene therapy delivery.
ClearPoint Neuro Reports Second Quarter 2025 Results
Record Revenue and Substantial Cash Infusion Highlight the Company's ‘Fast. Forward.' Strategy SOLANA BEACH, CA / ACCESS Newswire / August 12, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company...
ClearPoint Neuro Announces Progression of Key Partner Milestones throughout the Global Biologics and Drug Delivery Portfolio
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / August 4, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to ...
ClearPoint Neuro to Announce Second Quarter 2025 Results August 12, 2025
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / July 23, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation ...
ClearPoint Neuro Reports First Quarter 2025 Results
Record Revenue Highlighted by 70% Growth in Single-Use Navigation and Therapy Products SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 13, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"),...
ClearPoint Neuro Earnings Call Transcript: Q1 2025
Q1 2025 revenue grew 11% year-over-year to $8.5M, led by strong gains in neurosurgery navigation and biologics. New funding from Oberland Capital ensures multi-year strategic flexibility, while new product launches and a shift to subscription models position the company for accelerated growth.
ClearPoint Neuro Announces Investment of up to $110 Million by Oberland Capital with $33.5 Million Funded at Closing
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 12, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation t...